Trends in benzodiazepine prescribing under Medicare Part D in USA: outpatient settings 2005-2009

摘要: Objectives The objective of the study was to examine trend benzodiazepine prescribing under Medicare Part D formulary restriction. Methods A secondary data analysis conducted using National Ambulatory Medical Care Survey between 2005 and 2009. Subjects were identified from ambulatory physician office visits where primary payment source at least one US Food Drug Administration (FDA)-approved prescribed. Data graphically plotted further analysed segmented regression. Key findings An estimated 4.9 billion office-based physicians 2009 which 1.2 (24.24%) made by recipients. Of these, 86.9 million (7.38%) received FDA-approved including alprazolam (33.3%), lorazepam (24.4%), clonazepam (16.2%), diazepam (12.1%), etc. One year after passage exclusion, decreased 1.83%. However, it had dramatically increased (21.7%) in 2007. Results regression indicated that implementation drug benefits, with is significantly associated utilisation (P = 0.015). Conclusion The findings not exclusion. Several factors could explain this phenomenon: (1) economic perspectives, (2) supplement programmes, (3) patterns/habits, (4) elderly dependence on benzodiazepines. Despite benzodiazepines having been allowed formularies 2013, amendment may lead an even greater importance healthcare professionals policy makers providing comprehensive patient care ensures optional medication therapy outcomes.